Isaac Health is a specialist-led dementia care platform that guides patients through four phases of care: screening, specialist diagnosis, treatment and ongoing neurocognitive care management. The company provides at-home risk assessments including biomarker tests, connects patients to a network of more than 40 neurologists and other providers led by Harvard-trained neurologist Dr. Joel Salinas, and delivers both medication (e.g., cholinesterase inhibitors) and non-drug interventions such as cognitive therapy. Launched in 2022 and based in New York City, Isaac's platform recently became available in all 50 states and targets older adults showing early signs of dementia as well as people in their 40s and 50s. Isaac is partnered with more than 10 health plans and several health systems, is in-network with most major insurers including Medicare, and has screened more than 5,000 users on its platform. Its revenue is supported mainly by health plans and partially by patients depending on co-pays and deductibles. The company intends to use new funding to expand access to specialist-led cognitive care across the U.S. Isaac Health operates a virtual brain health and memory clinic platform that harnesses predictive machine learning to identify patients with cognitive and brain health conditions and deliver center-of-excellence-level care at scale. The company partners with health systems and payers to screen, diagnose, treat, and manage populations with brain health conditions and also offers a direct-to-consumer memory clinic service at myisaachealth.com. Isaac Health was launched in 2022 and is headquartered in New York. The company positions itself to address widespread access gaps: the Society of Actuaries classifies more than 20 U.S. states as "dementia neurology deserts," and the articles cite that 61% of dementia cases and 92% of mild cognitive impairment cases go undiagnosed. Isaac Health cites the recent FDA approval of a disease-modifying therapy for early-stage Alzheimer’s disease as increasing the need for specialist evaluation and follow-up. The business recently completed an oversubscribed $5.7 million Seed financing to accelerate development of its provider platform, scale operations, and expand strategic partnerships. The company plans to further develop and expand its brain health provider platform to advance screening, diagnosis, treatment, and management across communities.

Total raised

$16M

Funding rounds

2

Latest round

Series A

Latest activity

Aug 2025